EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

Anjali T Owens, Ahmad Masri, Theodore P Abraham, Lubna Choudhury, Florian Rader, John D Symanski, Aslan T Turer, Timothy C Wong, Albree Tower-Rader, Caroline J Coats, Michael A Fifer, Iacopo Olivotto und 11 weitere

Journal of Cardiac Failure · 2023

DOI: 10.1016/j.cardfail.2023.07.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2023. Verfasst von Anjali T Owens und 22 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania Perelman School …. Hauptthemen laut MEDLINE: Sequoia, Heart Failure, Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: British Heart Foundation, Cytokinetics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

•Aficamten is a next-generation cardiac myosin inhibitor (CMI)•CMIs are a novel treatment for obstructive hypertrophic cardiomyopathy (oHCM)•We report efficacy and safety of aficamten with disopyramide for refractory oHCM•In Cohort 3 of REDWOOD-HCM, aficamten plus disopyramide was well tolerated•Patients had improved left ventricular outflow tract gradient and NYHA class How this work applies to patients•Disopyramide is used to help relieve symptoms as a second-line option when patients with obstructive HCM have persistent limiting symptoms despite treatment with either a beta-blocker or calcium channel blocker.•REDWOOD-HCM Cohorts 1 & 2 showed that aficamten may safely help reduce obstruction in patients receiving treatment with beta-blockers and/or calcium channel blockers.•REDWOOD-HCM Cohort 3 now shows that aficamten appears to be a safe and effective add-on treatment in patients who remain refractory to all other medical therapies, and of the 13 patients studied, 11 (85%) showed some improvements in symptoms and 10 (77%) showed improvements in the degree of obstruction. The REDWOOD-HCM trial investigated aficamten, a drug designed to target the underlying cause of obstructive hypertrophic cardiomyopathy (oHCM). REDWOOD-HCM was a “Phase 2 trial” – a particular type of study for investigational therapies that are not yet approved. The trial tests whether the drug can be safely used in patients and makes a preliminary assessment of how well the drug works. Here, aficamten was tested in patients taking disopyramide as part of background treatment for their oHCM. The researchers conclude aficamten appeared safe and also showed promising treatment results. Further studies should be done to confirm the benefit of aficamten. Hypertrophic cardiomyopathy (HCM) is a heritable cardiomyopathy characterized by left ventricular (LV) hypertrophy and hypercontractility. Approximately 70% patients with HCM have LV outflow tract (LVOT) obstruction at rest or with provocation, and this is a strong determinant of adverse outcomes. Pharmacotherapy with beta-blockers or non-dihydropyridine calcium channel blockers (CCB) represents first-line treatment for symptomatic obstructive HCM (oHCM); the addition of disopyramide, a class 1A antiarrhythmic agent with negative inotropic effects, may provide additional relief as second-line therapy.1Sherrid MV Barac I McKenna WJ Elliott PM Dickie S Chojnowska L et al.Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.J Am Coll Cardiol. 2005; 45: 1251-1258Crossref PubMed Scopus (273) Google Scholar The use of disopyramide was exclusionary from the pivotal Phase 3 study for mavacamten, EXPLORER-HCM,2Ho CY Olivotto I Jacoby D Lester SJ Roe M Wang A et al.Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.Circ Heart Fail. 2020; 13e006853Crossref Scopus (39) Google Scholar likely out of concern for exacerbation of QT-interval prolongation potential with mavacamten, as reported in both Phase 1 evaluation in healthy volunteers and preclinical experiments with mavacamten.3CAMZYOSTM (mavacamten) capsules for oral use. Prescribing Information; revised September 2022. Available at https://packageinserts.bms.com/pi/pi_camzyos.pdf (accessed June 9 2023). Bristol-Myers Squibb Company, Princeton, NJ, USA.Google Scholar Aficamten, a next-in-class small molecule inhibitor of cardiac myosin, reduces pathologic hypercontractility in HCM. In the randomized, double-blind cohorts 1 and 2 of the Phase 2 REDWOOD-HCM study, aficamten added to beta-blockers and/or CCB was well tolerated and reduced LVOT gradients (LVOT-G).4Maron MS Masri A Choudhury L Olivotto I Saberi S Wang A et al.Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy.J Am Coll Cardiol. 2023; 81: 34-45Crossref Scopus (12) Google Scholar Patients treated with disopyramide as part of their therapeutic regimen for recalcitrant symptoms had been excluded from the prior cohorts in REDWOOD-HCM. As such these were included in a separate cohort primarily designed to evaluate the impact of aficamten on safety, although aficamten had already been shown to have a neutral effect on the QT interval in the Phase 1 study.5Malik FI Robertson LA Armas DR Robbie EP Osmukhina A Xu D et al.A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants.JACC Basic Transl Sci. 2022; 7: 763-775Crossref Scopus (9) Google Scholar Efficacy was also measured, with the key objective of establishing optimal doses for double-blind trials. Cohort 3 of REDWOOD-HCM is the first prospective study of aficamten with disopyramide in these medically refractory oHCM patients. New York Heart Association (NYHA) class II/III patients with oHCM (resting LVOT-G ≥50 mmHg or resting LVOT-G ≥30 mmHg and Valsalva LVOT-G ≥50 mmHg) on medical therapy (beta-blockers and/or CCB) plus disopyramide were enrolled in an open-label fashion. A placebo control was not felt to be necessary, as Cohorts 1 and 2 had already enrolled a combined 13 placebo-treated patients. In addition, the primary electrocardiographic safety metric of change from baseline in the corrected QT interval (QTc) did not require a placebo control in this cohort. Thus, all patients were assigned aficamten for a 10-week treatment period, with 2-weeks’ washout after Week 10. Aficamten (5, 10, 15 mg) was titrated based on site-read echocardiograms at 2-week intervals over 6 weeks. Doses were increased for left ventricular ejection fraction (LVEF) ≥50% and persistent obstruction (resting or Valsalva LVOT-G ≥30 mmHg or 50 mmHg, respectively), reduced if LVEF

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SequoiaHeart FailureCardiomyopathy, HypertrophicHumansDisopyramideAnti-Arrhythmia Agents

Stichwörter der Autor:innen

AficamtenREDWOOD-HCMobstructive hypertrophic cardiomyopathyrefractory obstructive hypertrophic cardiomyopathy

Substanzen

DisopyramideAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: Anjali.Owens@u…
  • Oregon Health and Science University, Portland, OR, USA.
  • University of California San Francisco, San Francisco, CA, USA.
  • Northwestern University Feinberg School of Medicine, Division of Cardiology, Chicago, IL, USA.
  • Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA.
  • Atrium Health, Sanger Heart & Vascular Institute, Charlotte, NC, USA.

Förderung

  • British Heart Foundation
  • Cytokinetics

Zitieren

APA

Owens, A. T., Masri, A., Abraham, T. P., Choudhury, L., Rader, F., Symanski, J. D., Turer, A. T., Wong, T. C., Tower-Rader, A., Coats, C. J., Fifer, M. A., Olivotto, I., Solomon, S. D., Watkins, H. C., Heitner, S. B., Jacoby, D. L., Kupfer, S., Malik, F. I., Meng, L., …, & REDWOOD-HCM INVESTIGATORS (2023). Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2023.07.003

Vancouver

Owens AT, Masri A, Abraham TP, Choudhury L, Rader F, Symanski JD, et al. Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3. Journal of Cardiac Failure. 2023. doi:10.1016/j.cardfail.2023.07.003

BibTeX
@article{Owens2023,
  author = {Owens, Anjali T and Masri, Ahmad and Abraham, Theodore P and Choudhury, Lubna and Rader, Florian and Symanski, John D and Turer, Aslan T and Wong, Timothy C and Tower-Rader, Albree and Coats, Caroline J and Fifer, Michael A and Olivotto, Iacopo and Solomon, Scott D and Watkins, Hugh C and Heitner, Stephen B and Jacoby, Daniel L and Kupfer, Stuart and Malik, Fady I and Meng, Lisa and Sohn, Regina and Wohltman, Amy and Maron, Martin S and REDWOOD-HCM INVESTIGATORS, REDWOOD-HCM INVESTIGATORS},
  title = {Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3},
  journal = {Journal of Cardiac Failure},
  year = {2023},
  doi = {10.1016/j.cardfail.2023.07.003}
}
Kostenlos starten →